FGL1 and metabolic dysfunction-associated steatotic liver disease: As a potential diagnostic biomarker and indicator of NAFLD, diabetes and obesity treatment response, FGL1 is a candidate target worthy of further study at the mechanistic level in the continual search for therapeutic remedies for these diseases.